miR‑454‑3p promotes of human glioma cell growth by targeting EGR3

Shen,Guoliang; Wu,Jian; Mou,Zhaohui; Chen,Danlong; Liu,Li; Li,Xing

doi:10.3892/etm.2019.8048

miR‑454‑3p promotes of human glioma cell growth by targeting EGR3

Authors:
- Guoliang Shen
- Jian Wu
- Zhaohui Mou
- Danlong Chen
- Li Liu
- Xing Li
View Affiliations

Affiliations: Department of Neurosurgery, The First People's Hospital of Taizhou, Taizhou, Zhejiang 318020, P.R. China
Published online on: September 25, 2019 https://doi.org/10.3892/etm.2019.8048
Pages: 4031-4039
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gliomas are the most common primary brain tumors in adults and are associated with high mortality rates. In the present study, the aim was to evaluate the role of miR‑454‑3p in the pathogenesis of human glioma and to explore the underlying mechanism. Reverse transcription‑quantitative PCR was performed to compare the expression levels of miR‑454‑3p in glioma and adjacent normal tissue. The effects of miR‑454‑3p on cell proliferation was tested by combining MTT and colony formation assays. Dual‑luciferase assay was used to identify the target gene of miR‑454‑3p. The results showed that miR‑454‑3p was upregulated in glioma tissues where it exerts a positively regulatory role on cell growth. Dual‑luciferase assay confirmed Early Growth Response 3 (EGR3) to be a target for miR‑454‑3p. Overexpression of EGR3 in glioma cells was found to impair miR‑454‑3p mimic‑induced cell proliferation. These results suggested that upregulated miR‑454‑3p served an important role in glioma tumorigenesis by targeting EGR3, which provided valuable insights into the underlying mechanism of the disease that may lead to possible novel therapeutic strategies.

View Figures

View References

1	Pan Y, Yuan F, Li Y, Wang G, Lin Z and Chen L: Bromodomain PHD-finger transcription factor promotes glioma progression and indicates poor prognosis. Oncol Rep. 41:246–256. 2019.PubMed/NCBI
2	Yan J, Xu C, Li Y, Tang B, Xie S, Hong T and Zeng E: Long non-coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL. J Cell Mol Med. 23:5518–5531. 2019. View Article : Google Scholar : PubMed/NCBI
3	Guo Y, Hong W, Wang X, Zhang P, Körner H, Tu J and Wei W: MicroRNAs in microglia: How do micrornas affect activation, inflammation, polarization of microglia and mediate the interaction between microglia and glioma? Front Mol Neurosci. 12:1252019. View Article : Google Scholar : PubMed/NCBI
4	Petrescu GED, Sabo AA, Torsin LI, Calin GA and Dragomir MP: MicroRNA based theranostics for brain cancer: Basic principles. J Exp Clin Cancer Res. 38:2312019. View Article : Google Scholar : PubMed/NCBI
5	Si W, Shen J, Zheng H and Fan W: The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 11:252019. View Article : Google Scholar : PubMed/NCBI
6	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
7	Omar HA, El-Serafi AT, Hersi F, Arafa ESA, Zaher DM, Madkour M, Arab HH and Tolba MF: Immunomodulatory MicroRNAs in cancer: Targeting immune checkpoints and the tumor microenvironment. FEBS J. Jul 15–2019.(Epub ahead of print) doi: 10.1111/febs.15000. View Article : Google Scholar : PubMed/NCBI
8	Ye X, Wei W, Zhang Z, He C, Yang R, Zhang J, Wu Z, Huang Q and Jiang Q: Identification of microRNAs associated with glioma diagnosis and prognosis. Oncotarget. 8:26394–26403. 2017.PubMed/NCBI
9	Zhang Y, Zhang R, Sui R, Chen Y, Liang H, Shi J and Piao H: MicroRNA-374a governs aggressive cell behaviors of glioma by targeting prokineticin 2. Technol Cancer Res Treat. 18:15330338188214012019. View Article : Google Scholar : PubMed/NCBI
10	Barciszewska AM: MicroRNAs as efficient biomarkers in high-grade gliomas. Folia Neuropathol. 54:369–374. 2016. View Article : Google Scholar : PubMed/NCBI
11	Liang HL, Hu AP, Li SL, Xie JP, Ma QZ and Liu JY: MiR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression. Asian Pac J Cancer Prev. 16:2397–2402. 2015. View Article : Google Scholar : PubMed/NCBI
12	Piwecka M, Rolle K, Belter A, Barciszewska AM, Żywicki M, Michalak M, Nowak S, Naskręt-Barciszewska MZ and Barciszewski J: Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol. 9:1324–1340. 2015. View Article : Google Scholar : PubMed/NCBI
13	Meyers KT, Marballi KK, Brunwasser SJ, Renda B, Charbel M, Marrone DF and Gallitano AL: The immediate early gene Egr3 is required for hippocampal induction of Bdnf by electroconvulsive stimulation. Front Behav Neurosci. 12:922018. View Article : Google Scholar : PubMed/NCBI
14	Chien MH, Lee WJ, Yang YC, Li YL, Chen BR, Cheng TY, Yang PW, Wang MY, Jan YH, Lin YK, et al: KSRP suppresses cell invasion and metastasis through miR-23a-mediated EGR3 mRNA degradation in non-small cell lung cancer. Biochim Biophys Acta Gene Regul Mech. 1860:1013–1024. 2017. View Article : Google Scholar : PubMed/NCBI
15	Maple A, Lackie RE, Elizalde DI, Grella SL, Damphousse CC, Xa C, Gallitano AL and Marrone DF: Attenuated late-phase Arc transcription in the dentate gyrus of mice lacking Egr3. Neural Plast. 2017:60630482017. View Article : Google Scholar : PubMed/NCBI
16	Oliveira Fernandes M and Tourtellotte WG: Egr3-dependent muscle spindle stretch receptor intrafusal muscle fiber differentiation and fusimotor innervation homeostasis. J Neurosci. 35:5566–5578. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zhang S, Xia C, Xu C, Liu J, Zhu H, Yang Y, Xu F, Zhao J, Chang Y and Zhao Q: Early growth response 3 inhibits growth of hepatocellular carcinoma cells via upregulation of Fas ligand. Int J Oncol. 50:805–814. 2017. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:e050052015. View Article : Google Scholar
20	Zhang Y, Chen J, Xue Q, Wang J, Zhao L, Han K, Zhang D and Hou L: Prognostic significance of MicroRNAs in glioma: A systematic review and meta-analysis. Biomed Res Int. 2019:40159692019.PubMed/NCBI
21	Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS and Canoll P: The role of myosin II in glioma invasion of the brain. Mol Biol Cell. 19:3357–3368. 2008. View Article : Google Scholar : PubMed/NCBI
22	Shao N, Wang L, Xue L, Wang R and Lan Q: Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 36:309–313. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kabekkodu SP, Shukla V, Varghese VK, Adiga D, Vethil Jishnu P, Chakrabarty S and Satyamoorthy K: Cluster miRNAs and cancer: Diagnostic, prognostic and therapeutic opportunities. Wiley Interdiscip Rev RNA. e15632019.PubMed/NCBI
24	Wang X, Liu B, Wen F and Song Y: MicroRNA-454 inhibits the malignant biological behaviours of gastric cancer cells by directly targeting mitogen-activated protein kinase 1. Oncol Rep. 39:1494–1504. 2018.PubMed/NCBI
25	Fu Q, Gao Y, Yang F, Mao T, Sun Z, Wang H, Song B and Li X: Suppression of microRNA-454 impedes the proliferation and invasion of prostate cancer cells by promoting N-myc downstream-regulated gene 2 and inhibiting WNT/β-catenin signaling. Biomed Pharmacother. 97:120–127. 2018. View Article : Google Scholar : PubMed/NCBI
26	Zhou L, Qu YM, Zhao XM and Yue ZD: Involvement of miR-454 overexpression in the poor prognosis of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 20:825–829. 2016.PubMed/NCBI
27	Zhu DY, Li XN, Qi Y, Liu DL, Yang Y, Zhao J, Zhang CY, Wu K and Zhao S: MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN. Biomed Pharmacother. 81:79–85. 2016. View Article : Google Scholar : PubMed/NCBI
28	Cao ZG, Li JJ, Yao L, Huang YN, Liu YR, Hu X, Song CG and Shao ZM: High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. Oncotarget. 7:64900–64909. 2016. View Article : Google Scholar : PubMed/NCBI
29	Zhang P, Yang X, Wang L, Zhang D, Luo Q and Wang B: Overexpressing miR-335 inhibits DU145 cell proliferation by targeting early growth response 3 in prostate cancer. Int J Oncol. 54:1981–1994. 2019.PubMed/NCBI
30	Zhu D, He X, Duan Y, Chen J, Wang J, Sun X, Qian H, Feng J, Sun W, Xu F and Zhang L: Expression of microRNA-454 in TGF-β1-stimulated hepatic stellate cells and in mouse livers infected with Schistosoma japonicum. Parasit Vectors. 7:1482014. View Article : Google Scholar : PubMed/NCBI